KALA BIO to Present at Jefferies Global Healthcare Conference
KALA BIO (NASDAQ:KALA) will present at the Jefferies Global Healthcare Conference on June 5, 2024, in New York, NY. Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer, will deliver the presentation at 12:30 p.m. ET. The company's management team is also available for one-on-one meetings on the same day. The presentation's webcast and archived recording will be accessible on the KALA website.
- KALA BIO's participation in a prestigious conference like Jefferies Global Healthcare Conference elevates its visibility among investors and industry leaders.
- Presentation to be delivered by Kim Brazzell, Ph.D., adds credibility, emphasizing the expertise in their R&D department.
- Opportunity for one-on-one meetings with management could facilitate meaningful investor relations and potential partnerships.
- No new financial data or clinical trial results were provided in the announcement.
- The event may not directly translate to immediate financial benefits or significant stock price movements.
ARLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Jefferies Global Healthcare Conference being held in New York, NY on Wednesday, June 5, 2024 at 12:30 p.m. ET. Management will also be available for one-on-one meetings on Wednesday, June 5, 2024.
To access the webcast and subsequent archived recording of the presentation, please visit the “Presentations” section of the KALA website at www.kalarx.com.
About KALA BIO, Inc.
KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.
Investor Contact:
Taylor Steiner
taylor.steiner@precisionaq.com
212-362-1200
FAQ
When will KALA BIO present at the Jefferies Global Healthcare Conference?
Who will represent KALA BIO at the Jefferies Global Healthcare Conference?
How can I access KALA BIO's presentation at the Jefferies Global Healthcare Conference?
Will there be opportunities for one-on-one meetings with KALA BIO's management at the conference?
